✦ LIBER ✦

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B

✍ Scribed by Stephanos J. Hadziyannis, Dimitrios Vassilopoulos

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1153 The impact of interferon-alfa (IFNA

✍ PAPATHEODORIDIS, G; CHOLONGITAS, E; KANTA, E; PETRAKI, K; KETIKOGLOU, I; MANESIS 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

The cost-effectiveness of long-term anti

✍ Lacey, L. F. (author);Gane, E. (author) 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

The cost-effectiveness of long-term anti

✍ Lacey, L. F. (author);Gane, E. (author) 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

[524] PREDICTORS OF RESPONSE IN PATIENTS

✍ J. Li; H. Zhao; C.-W. Si; Y.-X. Zhang; X.-Y. Chen; L. Wang; X.-P. Tang 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 244 KB

Impact of interferon-alpha therapy on li

✍ G. V. Papatheodoridis; K. Petraki; E. Cholongitas; E. Kanta; I. Ketikoglou; E. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

731 CHANGES OF SERUM APOPTOTIC CASPASE A

✍ G.V. Papatheodoridis; J. Giannousis; S. Manolakopoulos; E. Hadziyannis; A. Georg 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 146 KB